Vir Biotechnology and Gilead Sciences have agreed to develop three dual-masked T-cell engager programmes under a deal worth up to approximately $1.88 billion. The $90 million upfront package includes cash and equity, while most of the headline value depends on future development and commercial milestones.
Bispecific T-cell engagers developed for blood cancers are being repurposed to eliminate pathogenic B cells and plasma cells in severe autoimmune disease, potentially offering CAR-T-like depth without individualized cell manufacturing.
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
Vir Biotechnology’s VIR-5500 shows early promise in metastatic prostate cancer. Find out what changes, what remains uncertain, and what comes next.